mercredi 30 septembre 2026
RechercherExplore
fr.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 15, 2025

4 Medical Device Stocks to Buy for Healthy Returns in 2026

View original at finance.yahoo.com
4 Medical Device Stocks to Buy for Healthy Returns in 2026 2025 brought ups and downs for the MedTech industry. Under President Trump’s second term, shifting trade policies, including new and heightened threats of tariffs, sanctions and other restrictions, created significant uncertainties…
Opening lines of the source · short snapshot — read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • IDEXX's 2026 revenues and EPS are likely to increase 8.9% and 11.6%, respectively

    80% confidence

  • For 2026, Boston Scientific revenues and EPS are expected to jump 11.1% and 13.6%, respectively

    80% confidence

  • Intuitive Surgical carries a Zacks Rank #1 (Strong Buy)

    80% confidence

  • The digital twins market is forecasted to expand at a 16.6% CAGR between 2025 and 2032

    80% confidence

  • The MedTech industry generated $584 billion in revenues in 2025, marking its seventh consecutive year of top-line growth

    80% confidence

  • Boston Scientific carries a Zacks Rank #2 (Buy)

    80% confidence

  • Insulet holds a Zacks Rank #2 (Buy)

    80% confidence

  • M&A activity shifted toward fewer but larger deals, with average transaction size rising 11% from 2024

    80% confidence

  • The global medical device market is expected to expand at a CAGR of 5.94% from 2026 to 2035

    80% confidence

  • IDEXX plans to expand the Cancer Dx franchise in 2026 by adding mast cell tumor and introducing it in international markets

    80% confidence

  • IDEXX Laboratories carries a Zacks Rank #2 (Buy)

    80% confidence

  • For 2026, Intuitive Surgical revenues are expected to grow 14.3%, whereas earnings per share are expected to rise 11.2%

    80% confidence

  • Through September 2025, the FDA's list of AI-enabled device authorizations included more than 250 devices, with Radiology taking the lead

    80% confidence

  • For 2026, Insulet revenues and EPS are expected to grow 19.8% and 26.3%, respectively

    80% confidence

  • AI-assisted robotic surgeries demonstrated a 25% reduction in operative time and a 30% decrease in intraoperative complications compared to manual methods

    80% confidence

  • More Omnipod 5 rollouts are planned in 2026, while Libre 3 integration in the United States remains on track for the first half of 2026

    80% confidence

Data points we hold from this source

U.S. Food and Drug Administration · ai device authorizations250 devices
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
The Agentic Takeover of the CFO's Office
Enterprise finance software vendors—BlackLine, OneStream, Numero AI, and Oracle—are racing to embed autonomous AI agents into core financial operations (close, consolidation, reporting), backed by consolidation M&A (Numero-Royu, BlackLine-WiseLayer), fresh leadership hires, and survey data showing nearly a quarter of CFOs plan to boost AI spending over 50%. Adoption momentum is strong even as at least one bellwether (Oracle) sees its stock lag year-to-date, suggesting the market hasn't yet fully priced in the shift from AI-as-feature to AI-as-agent in finance.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Morgan Stanley & Co. LLC
Two significantly different EPS values (10.21 vs 2.68 USD_per_share) are reported for Morgan Stanley on the same observation date (2025-12-31). Fact A specifies FY 2025, while Fact B's 'N/A' fiscal period is ambiguous. If both represent FY 2025 annual EPS, these values directly conflict. The magnitude of the difference (3.8x) is too large to attribute to rounding or minor calculation variations. The missing fiscal period in Fact B raises data quality concerns, but same-date observation + same attribute should reference the same period.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,984
faits reliés à leur source — et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,984 faits vérifiés avec la source5,315 documents sources archivés
Interrogez ces données → isubstrate.com
4 Medical Device Stocks to Buy for Healthy Returns in 2026 — Source | Via News | fr.VIA.NEWS